Roche announced results from a Phase II clinical study of RG7204 (PLX4032), an inhibitor targeting the BRAF protein that is found in half of metastatic melanoma tumors.&nbs...

WASHINGTON, D.C.— For years, treatment options for patients with advanced melanoma have been bleak, with survival averaging around one year after diagnosis.  But...

WASHINGTON, D.C.—Melanoma’s role as the number one form of cancer in young adults may be fueled by pervasive myths and misunderstandings about risk factors, and...

The Melanoma Research Foundation (MRF) is deeply saddened to learn of the loss of famed Hollywood producer and writer Stephen J. Cannell, who recently passed away from...

The MRF submitted a letter to the editor in response to a recent article in The New York Times, “When Testing a Drug Means Withholding It.”  The article fo...

The New England Journal of Medicine recently published an article focused on indoor tanning, written by scientific advisor to the MRF and chair of the department of dermato...

Contact: Berna Diehl Jones Public Affairs (202) 591-4045 Berna@JonesPA.com HILLSBOROUGH, N.J.—As summertime comes to a close, many families have left behind long, hot...

USA TODAY and NBC News report on results from a study highlighting a promising new therapy for metastatic melanoma.  The new research, published in the New England Jou...

Earlier this week, pharmaceutical company Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted a priority review for Ipilimumab, an i...

HILLSBOROUGH, N.J.—The recent debut of “The Big C” on Showtime has placed some of Hollywood’s spotlight on melanoma, the deadliest form of skin canc...

The Melanoma Research Foundation is proud to announce new research funding opportunities for medical students.  Approximately five research grants will be awarded, all...

The Melanoma Research Foundation (MRF) has partnered with UVSunSense™ to promote sun safety.   The UVSunSense™ wristband has a special coating&nb...